New Research Reports

Retail Research

Retail Research

With an upside of 12% from the CMP, we maintain our BUY rating on the stock

With a 6% upside from the CMP, we maintain our HOLD rating on the stock.

Asian markets are trading positively after the White House said that U.S. President Donald Trump and Chinese President Xi Jinping were set to hold talks next week. Nikkei is trading up by 1.39%, Hang Seng is trading up by 0.68% and Shanghai Composite is trading up by 0.32%.

we recommend a BUY on the stock with a target price of Rs 3,815 / implying an upside of 10 from the CMP

Q2FY26 Earnings Wrap - Week II

Newsletter

Q2FY26 Upbeat numbers across parameters - Sales stood at 1654 crore, reflecting a ~35% YoY growth and a growth of ~5.3% QoQ. The CDMO business saw impressive growth of 58% YoY, reaching 471 crore. Generic FDF also grew 58% YoY to 518 crore and the Generic APIs segment grew ~11% YoY to 617 crore. EBITDA stood at 403 crore with a margin of 24.4%, marking a significant improvement of 979 basis points YoY. PAT stood 193.8 crore, driven by a favourable product mix and strong operational performance....

Q2FY26 Performance: Reported revenue came in at 1823 crore, (up 12.4% YoY) with box office revenue of 983 crore (up 17.4% YoY). The footfalls were up ~15% YoY at 44.5 million and (Average Ticket Prices) ATP at 262 was up 1.9% YoY. Ad revenues were up ~15% YoY at 126 crore. F&B revenues were up 12.4% YoY at ...

About the stock: Hindustan Unilever (HUL) is India's largest FMCG company with presence of more than 90 years. The company has portfolio of 50+ brands spanning to various categories such as detergents, personal wash and skin care & colour cosmetics. 80% of revenues come from products having leadership positioning in...

Quarterly Update Q2FY26

Management expects a gradual demand recovery in H2FY26E, supported by improving macro indicators and internal execution initiatives.

IndusInd Bank is undergoing a strategic recalibration under new leadership, balancing near-term prudence with medium-term growth ambitions.

Rossari Biotech continues to execute well operationally, leveraging R&D intensity and export expansion to offset pricing headwinds.

Colgate’s Q2FY26 result reaffirms that business remains structurally fatigued, with no visible triggers for a turnaround. Revenue declined 6.2% YoY, implying a 7-8% volume decline amid GST-led destocking and continued competitive intensity.

END OF DAY SUMMARY

Retail Research

MARKET SNAPSHOT

Quarterly Update Q2FY26